GGrantIndex
← Leaderboards

William Irving Sivitz

University Of Iowa

$3,567,554
Attributed
$3,567,554
Total exposure
17
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $504.5K · FY200523
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$3,567,554 · 16
VA$0 · 1

By mechanism

R01$2,136,819 · 2
M01$909,808 · 13
P30$520,927 · 1
I01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Mitochondria

Research focus

MitochondriaObesityDiabetes MellitusRodentCellsMetabolicProductionBrown FatAdipocytesSuperoxidesLipid MetabolismClinical ResearchHuman SubjectLaboratoriesBaseAttentionAccountingFatty Acid Glycerol EstersAntioxidantsAgingEquilibriumInvestigationDiabetic NephropathyCultured Cells

Grant awards (39)

UCP1 and the regulation of mitochondrial respiration in brown adipose tissue by oxaloacetate$315,000
R01 · FY2023 · DK · contact PI
UCP1 and the regulation of mitochondrial respiration in brown adipose tissue by oxaloacetate$315,000
R01 · FY2022 · DK · contact PI
UCP1 and the regulation of mitochondrial respiration in brown adipose tissue by oxaloacetate$315,000
R01 · FY2021 · DK · contact PI
UCP1 and the regulation of mitochondrial respiration in brown adipose tissue by oxaloacetate$315,000
R01 · FY2020 · DK · contact PI
Mitochondrial-targeted CoQ analogs: Bioenergetic Effects in Obesity$0
I01 · FY2017 · VA · contact PI
Mitochondrial-targeted CoQ analogs: Bioenergetic Effects in Obesity$0
I01 · FY2016 · VA · contact PI
Mitochondrial-targeted CoQ analogs: Bioenergetic Effects in Obesity$0
I01 · FY2015 · VA · contact PI
Mitochondrial-targeted CoQ analogs: Bioenergetic Effects in Obesity$0
I01 · FY2014 · VA · contact PI
Mitochondrial-targeted CoQ: Metabolic and Redox Effects and role in Diabetes$0
I01 · FY2013 · VA · contact PI
Mitochondrial-targeted CoQ: Metabolic and Redox Effects and role in Diabetes$0
I01 · FY2012 · VA · contact PI
Mitochondrial-targeted CoQ: Metabolic and Redox Effects and role in Diabetes$0
I01 · FY2011 · VA · contact PI
Mitochondrial-targeted CoQ: Metabolic and Redox Effects and role in Diabetes$0
I01 · FY2011 · VA · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)$90,092
M01 · FY2007 · RR · contact PI
EDIC (EPIDEMIOLOGY OF DIABETES INTERVENTIONS & COMPLICATIONS)$8,956
M01 · FY2007 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)$265,363
M01 · FY2006 · RR · contact PI
Mitochondrial respiratory uncoupling and the pathogenes*$215,319
R01 · FY2006 · HL · contact PI
EDIC (EPIDEMIOLOGY OF DIABETES INTERVENTIONS & COMPLICATIONS)$23,823
M01 · FY2006 · RR · contact PI
ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES (ACCORD)$248,635
M01 · FY2005 · RR
Mitochondrial respiratory uncoupling and the pathogenes*$220,500
R01 · FY2005 · HL
EDIC (EPIDEMIOLOGY OF DIABETES INTERVENTIONS &COMPLICATIONS)$20,719
M01 · FY2005 · RR
GENETIC STUDIES OF DIABETIC COMPLICATIONS IN EPIDEMIOLOGY OF DIABETES$3,237
M01 · FY2005 · RR
THE GENETICS OF KIDNEYS IN DIABETES (GOKIND) STUDY$648
M01 · FY2005 · RR
Mitochondrial respiratory uncoupling and the pathogenes*$220,500
R01 · FY2004 · HL
Action to Control Cardiovascular Risk in Diabetes ACCORD$131,888
M01 · FY2004 · RR
EDIC (Epidemiology of Diabetes Interventions &Complications)$18,890
M01 · FY2004 · RR
Genetic Study of Diabetic Complication in DMEpidemiology$5,060
M01 · FY2004 · RR
The Genetics of Kidneys in Diabetes (GoKinD) Study$4,385
M01 · FY2004 · RR
Mitochondrial respiratory uncoupling and the pathogenes*$220,500
R01 · FY2003 · HL
CORE--COMPUTER SERVICES$211,312
P30 · FY2002 · DK
VASCULAR AND METABOLIC EFFECTS IN THE TREATMENT OF TYPE II DIABETES$0
M01 · FY2002 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION &COMPLICATIONS$0
M01 · FY2002 · RR
CORE--COMPUTER SERVICES$211,312
P30 · FY2001 · DK
VASCULAR AND METABOLIC EFFECTS IN THE TREATMENT OF TYPE II DIABETES$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION &COMPLICATIONS$0
M01 · FY2001 · RR
CORE--COMPUTER SERVICES$98,303
P30 · FY2000 · DK
PIMAGEDINE IN PATIENTS WITH TYPE II DIABETES MELLITUS AND DIABETIC NEPHROPATHY$22,028
M01 · FY2000 · RR
VASCULAR AND METABOLIC EFFECTS IN THE TREATMENT OF TYPE II DIABETES$22,028
M01 · FY2000 · RR
AMINOGUANIDINE IN DIABETIC PATIENT WITH OVERT DIABETIC NEPHROPATHY$22,028
M01 · FY2000 · RR
EPIDEMIOLOGY OF DIABETES INTERVENTION &COMPLICATIONS$22,028
M01 · FY2000 · RR